You searched for "AMD"
Four year outcomes of macular degeneration treated with ranibizumab
1 February 2014
| Brian Ang
|
EYE - Vitreo-Retinal
The authors report on a retrospective study of neovascular age-related macular degeneration (AMD) patients treated with a variable ranibizumab dosing regimen over a period of four years (from January 2007 to December 2011). A total of 600 treatment naïve eyes...
Quantum technology first in eye disease detection
8 January 2024
|
quantum, AMD, disease prevention, Age-related macular degeneration, CEVR, innovation
Scientists are working on a new device that could lead to a reduction in the number of people who go blind from age-related macular degeneration (AMD).
PRN Ranibizumab verses continuous aflibercept in UK clinical practice
1 October 2018
| Jonathan Chan
|
EYE - Vitreo-Retinal
This was a multicentre (21 UK hospitals), national EMR study on treatment naïve nAMD eyes, undergoing predominantly as needed (PRN) Ranibizumab or continuous (fixed or treat and extend - (F/TE)) Aflibercept (Af). The primary outcome was change in vision at...
Efficacy and safety of intravitreal faricimab in nAMD, DME and RVO
30 January 2025
| Sofia Rokerya
|
EYE - Vitreo-Retinal
This paper is an analysis of data extracted from 13 eligible studies in the context of neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO), collected from systematic literature search of MEDLINE, Embase, and Cochrane...
Clinical outcomes of AMT in acute ocular chemical injury
1 August 2017
| Jonathan Chan
|
EYE - Cornea, EYE - General
|
Cornea, Inflammation, Ocular surface, Stem Cells, Treatment Surgery
This is a retrospective study of patients from two units in Germany and UK between 1998 and 2008. The ocular chemical burns were classified by Roper-Hall and Dua classifications. A total of 72 eyes of 54 patients aged 37.3 years...
New partnership to prevent unnecessary sight loss
13 December 2022
Sight loss charity the Macular Society has announced a new partnership with OcuPlan, a service designed to give patients with long-term eye conditions such as macular disease affordable access to specialist care to prevent unnecessary sight loss.
It’s not all about ARED - Time for a pragmatic approach to nutrition for eye health?
1 April 2016
| Christine Purslow (Prof)
|
EYE - Cornea
Advances in treatment for retinal diseases involving neovascularisation have undoubtedly changed the future of eye care across the UK for the better, but also created great challenges for service delivery in ophthalmology, particularly within the NHS. Some statistics are starting...
Update on emerging therapies for age-related macular degeneration
4 December 2023
| Rod McNeil
|
EYE - Vitreo-Retinal
The 23rd European Society of Retina Specialists (EURETINA) Congress, held in Amsterdam, the Netherlands, provided a timely update on anti-complement therapy for geographic atrophy and emerging investigational therapies for neovascular age-related macular degeneration. Anti-complement therapy for geographic atrophy Geographic atrophy...
Considerations in the management of retinal disorders
1 October 2017
| Rod McNeil
|
EYE - Vitreo-Retinal
Vision research presentations and publications explore practice considerations in the management of AMD and diabetic retinopathy. Over the past two decades in Europe there has been a decreasing prevalence of age-related macular degeneration (AMD) and an improvement in visual acuity...
Report on preoperative visual acuities of patients from two AMM surgical trips to Magdalena, Northern Bolivia
The Andean Medical Mission (AMM), founded in 2012, recently celebrated 12 years of dedicated service in the Bolivian Amazon, aiming to eliminate avoidable blindness. Over this period, AMM has successfully performed over 1700 surgeries, including for children with congenital or...Patients blinded by stem cells! How safe are they really?
Simerdip Kaur takes a look at the latest ophthalmology-related news stories and asks which are based on facts and which are ‘fake news’. Headline: Patients blinded by stem cells! How safe are they really? Ever since the successful results following...
Brolucizumab in age-related macular degeneration, HAWK Study
3 October 2023
| Kurt Spiteri Cornish
|
EYE - Vitreo-Retinal
|
Neovascular age-related macular degeneration, aflibercept, anti-vascular endothelial growth factor therapy, brolucizumab, commercial formulation
The aim of the study was to collect additional data on efficacy and safety of brolucizumab 6mg intended for commercialization in age-related macular degeneration (AMD) (with an increase in pH and decrease in polysorbate concentration). The HAWK Study was a...
